Pulmonary surfactant for neonatal respiratory disorders

Current Opinion in Pediatrics

Volumn 15, Issue 2, 2003, Pages 149-154

  Merrill, Jeffrey D ^a   Ballard, Roberta A ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTIFICIAL LUNG SURFACTANT; LUCINACTANT; LUNG SURFACTANT EXTRACT; SURFACTANT; SURFACTANT ASSOCIATED PROTEIN; SURFACTANT PROTEIN A; SURFACTANT PROTEIN B; SURFACTANT PROTEIN C; SURFACTANT PROTEIN D;

ARTIFICIAL VENTILATION; BLOOD OXYGENATION; BOLUS INJECTION; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG ANALYSIS; DRUG EFFICACY; DRUG FORMULATION; DRUG SYNTHESIS; ENDOTRACHEAL INTUBATION; HUMAN; IMMUNITY; LUNG DYSPLASIA; LUNG FUNCTION; LUNG INJURY; MECONIUM ASPIRATION; META ANALYSIS; NEONATAL RESPIRATORY DISTRESS SYNDROME; NEWBORN CARE; NEWBORN MORBIDITY; NEWBORN MORTALITY; NONHUMAN; OUTCOMES RESEARCH; PNEUMONIA; POSITIVE END EXPIRATORY PRESSURE; PREMATURITY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; REVIEW;

ANIMALS; HUMANS; INFANT, NEWBORN; MECONIUM ASPIRATION SYNDROME; PNEUMONIA; PULMONARY SURFACTANTS; RESPIRATORY DISTRESS SYNDROME, NEWBORN; RESPIRATORY TRACT DISEASES;

EID: 0037377025     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008480-200304000-00002     Document Type: Review

References (62)

1. Jobe AH: Pulmonary surfactant therapy. N Engl J Med 1993, 328:861-868.
2. Carlton DP, Cho SC, Davis P, et al.: Surfactant treatment at birth reduces lung vascular injury and edema in preterm lambs. Pediatr Res 1995, 37:265-270.
3. Crouch E and Wright JR: Surfactant proteins a and d and pulmonary host defense. Annu Rev Physiol 2001, 63:521-554.
4. Hawgood S, Poulain FR: The pulmonary collectins and surfactant metabolism. Annu Rev Physiol 2001, 63:495-519. An excellent review of the latest research on SP-A and SP-D structure and function.
5. Cole FS, Hamvas A, Rubinstein P, et al.: Population-based estimates of surfactant protein B deficiency. Pediatrics 2000, 105:538-541.
6. Nogee LM, Dunbar AE 3rd, Wert SE, et al.: A mutation in the surfactant protein C gene associated with familial interstitial lung disease. N Engl J Med 2001, 344:573-579.
7. Avery ME and Mead J: Surface properties in relation to atelectasis and hyaline membrane disease. American Journal of Diseases of Childhood 1959, 97:517-523.
8. Fujiwara T, Maeta H, Chida S, et al.: Artificial surfactant therapy in hyaline-membrane disease. Lancet 1980, 1:55-59.
9. Soll RF: Synthetic surfactant for respiratory distress syndrome in preterm infants. Cochrane Database Syst Rev 2000, CD001149.
10. Soll RF: Prophylactic natural surfactant extract for preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev 2000, CD000511.
11. Soll RF, Blanco F: Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome. Cochrane Database Syst Rev 2001, CD000144. The latest meta-analysis of trials of natural versus synthetic surfactants, clearly demonstrating the superiority of natural surfactants in prevention of acute pulmonary morbidities in preterm infants.
12. Soll RF: Multiple versus single dose natural surfactant extract for severe neonatal respiratory distress syndrome. Cochrane Database Syst Rev 2000, CD000141.
13. Grossmann G, Nilsson R, Robertson B: Scanning electron microscopy of epithelial lesions induced by artificial ventilation of the immature neonatal lung; the prophylactic effect of surfactant replacement. Eur J Pediatr 1986, 145:361-367.
14. Bjorklund LJ, Ingimarsson J, Curstedt T, et al.: Manual ventilation with a few large breaths at birth compromises the therapeutic effect of subsequent surfactant replacement in immature lambs. Pediatr Res 1997, 42:348-355.
15. Soll RF, Morley CJ: Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev 2001, CD000510.
16. Van Marter LJ, Allred EN, Pagano M, et al.: Do clinical markers of barotrauma and oxygen toxicity explain interhospital variation in rates of chronic lung disease? The Neonatology Committee for the Developmental Network. Pediatrics 2000, 105:1194-1201.
17. Verder H, Albertsen P, Ebbesen F, et al.: Nasal continuous positive airway pressure and early surfactant therapy for respiratory distress syndrome in newborns of less than 30 weeks' gestation. Pediatrics 1999, 103:E24.
18. Lam BC: Surfactant lavage for the management of severe meconium aspiration syndrome. Biol Neonate 1999, 76:10-14.
19. Moses D, Holm BA, Spitale P, et al.: Inhibition of pulmonary surfactant function by meconium. Am J Obstet Gynecol 1991, 164:477-481.
20. Sun B, Curstedt T, Robertson B: Surfactant inhibition in experimental meconium aspiration. Acta Paediatr 1993, 82:182-189.
21. Sun B, Curstedt T, Song GW, et al.: Surfactant improves lung function and morphology in newborn rabbits with meconium aspiration. Biol Neonate 1993, 63:96-104.
22. Auten RL, Notter RH, Kendig JW, et al.: Surfactant treatment of full-term newborns with respiratory failure. Pediatrics 1991, 87:101-107.
23. Khammash H, Perlman M, Wojtulewicz J, et al.: Surfactant therapy in full-term neonates with severe respiratory failure. Pediatrics 1993, 92:135-139.
24. Findlay RD, Taeusch HW, Walther FJ: Surfactant replacement therapy for meconium aspiration syndrome. Pediatrics 1996, 97:48-52.
25. Lotze A, Mitchell BR, Bulas DI, et al.: Multicenter study of surfactant (beractant) use in the treatment of term infants with severe respiratory failure. Survanta in Term Infants Study Group. J Pediatr 1998, 132:40-47.
26. Balaraman V, Sood SL, Finn KC, et al.: Physiologic response and lung distribution of lavage versus bolus Exosurf in piglets with acute lung injury. Am J Respir Crit Care Med 1996, 153:1838-1843.
27. Meister JC, Balaraman V, Ku T, et al.: Lavage administration of dilute recombinant surfactant in acute lung injury in piglets. Pediatr Res 2000, 47:240-245.
28. Paranka MS, Walsh WF and Stancombe BB: Surfactant lavage in a piglet model of meconium aspiration syndrome. Pediatr Res 1992, 31:625-628.
29. Ibara S, Ikenoue T, Murata Y, et al.: Management of meconium aspiration syndrome by tracheobronchial lavage and replacement of Surfactant-TA. Acta Paediatr Jap 1995, 37:64-67.
30. Robinson TW, Roberts AM: Effects of exogenous surfactant on gas exchange and compliance in rabbits after meconium aspiration. Pediatr Pulmonol 2002, 33:117-123. An article demonstrating improved clinical response after slow infusion of surfactant as compared with the usual bolus method of delivery.
31. Ingenito EP, Mora R, Cullivan M, et al.: Decreased surfactant protein-B expression and surfactant dysfunction in a murine model of acute lung injury. Am J Respir Cell Mol Biol 2001, 25:35-44.
32. Augusto L, Le Blay K, Auger G, et al.: Interaction of bacterial lipopolysaccharide with mouse surfactant protein C inserted into lipid vesicles. Am J Physiol Lung Cell Mol Physiol 2001, 281:L776-785.
33. Lema G, Dryja D, Vargas I, et al.: Pseudomonas aeruginosa from patients with cystic fibrosis affects function of pulmonary surfactant. Pediatr Res 2000, 47:121-126.
34. Schmidt R, Meier U, Yabut-Perez M, et al.: Alteration of fatty acid profiles in different pulmonary surfactant phospholipids in acute respiratory distress syndrome and severe pneumonia. Am J Respir Crit Care Med 2001, 163:95-100.
35. Kerr MH and Paton JY: Surfactant protein levels in severe respiratory syncytial virus infection. Am J Respir Crit Care Med 1999, 159:1115-1118.
36. Atochina EN, Beers MF, Scanlon ST, et al.: P. carinii induces selective alterations in component expression and biophysical activity of lung surfactant. Am J Physiol Lung Cell Mol Physiol 2000, 278:L599-609.
37. Haczku A, Atochina EN, Tomer Y, et al.: Aspergillus fumigatus-induced allergic airway inflammation alters surfactant homeostasis and lung function in BALB/c mice. Am J Respir Cell Mol Biol 2001, 25:45-50.
38. Beers MF, Solarin KO, Guttentag SH, et al.: TGF-beta1 inhibits surfactant component expression and epithelial cell maturation in cultured human fetal lung. Am J Physiol 1998, 275:L950-960.
39. Bachurski CJ, Pryhuber GS, Glasser SW, et al.: Tumor necrosis factor-alpha inhibits surfactant protein C gene transcription. J Biol Chem 1995, 270:19402-19407.
40. Glumoff V, Vayrynen O, Kangas T, et al.: Degree of lung maturity determines the direction of the interleukin-1-induced effect on the expression of surfactant proteins. Am J Respir Cell Mol Biol 2000, 22:280-288.
41. De Dooy JJ, Mahieu LM, Van Bever HP: The role of inflammation in the development of chronic lung disease in neonates. Eur J Pediatr 2001, 160:457-463.
42. Hallman M, Glumoff V, Ramet M: Surfactant in respiratory distress syndrome and lung injury. Comp Biochem Physiol A Mol Integr Physiol 2001, 129:287-294.
43. Mishra A, Weaver TE, Beck DC, et al.: Interleukin-5-mediated allergic airway inflammation inhibits the human surfactant protein C promoter in transgenic mice. J Biol Chem 2001, 276:8453-8459.
44. Rudiger M, Friedrich W, Rustow B, et al.: Disturbed surface properties in preterm infants with pneumonia. Biol Neonate 2001, 79:73-78.
45. Herting E, Jarstrand C, Rasool O, et al.: Experimental neonatal group B streptococcal pneumonia: effect of a modified porcine surfactant on bacterial proliferation in ventilated near-term rabbits. Pediatr Res 1994, 36:784-791.
46. Herting E, Sunday B, Jarstrand C, et al.: Surfactant improves lung function and mitigates bacterial growth in immature ventilated rabbits with experimentally induced neonatal group B streptococcal pneumonia. Arch Dis Child Fetal Neonatal Ed 1997, 76:F3-8.
47. Herting E, Gefeller O, Land M, et al.: Surfactant treatment of neonates with respiratory failure and group B streptococcal infection. Members of the Collaborative European Multicenter Study Group. Pediatrics 2000, 106:957-964. This article reports on the largest investigation, albeit retrospective, of surfactant treatment of neonates with infection and respiratory compromise.
48. Horowitz S, Watkins RH, Auten RL, Jr, et al.: Differential accumulation of surfactant protein A, B, and C mRNAs in two epithelial cell types of hyperoxic lung. Am J Respir Cell Mol Biol 1991, 5:511-515.
49. Allred TF, Mercer RR, Thomas RF, et al.: Brief 95% O2 exposure effects on surfactant protein and mRNA in rat alveolar and bronchiolar epithelium. Am J Physiol 1999, 276:L999-L1009.
50. King RJ, Coalson JJ, deLemos RA, et al.: Surfactant protein-A deficiency in a primate model of bronchopulmonary dysplasia. Am J Respir Crit Care Med 1995, 151:1989-1997.
51. Savani RC, Godinez RI, Godinez MH, et al.: Respiratory distress after intra-tracheal bleomycin: selective deficiency of surfactant proteins B and C. Am J Physiol Lung Cell Mol Physiol 2001, 281:L685-696. Provides experimental evidence of surfactant protein down regulation with acute lung injury and demonstrates recovery of surface properties, as measured in vitro, after the addition of exogenous SP-B.
52. Beers MF, Hamvas A, Moxley MA, et al.: Pulmonary surfactant metabolism in infants lacking surfactant protein B. Am J Respir Cell Mol Biol 2000, 22:380-391. This report demonstrates alteration of surfactant protein concentrations in preterm infants with BPD to levels similar to term infants with congenital SP-B deficiency.
53. Merrill JD, Ballard RA, Godinez RI, et al.: Surfactant function and composition in premature infants with lung disease. Pediatr Res 2002, 51:347A.
54. Pandit PB, Dunn MS, Kelly EN, et al.: Surfactant replacement in neonates with early chronic lung disease. Pediatrics 1995, 95:851-854.
55. Lu KW, William Taeusch H, Robertson B, et al.: Polymer-surfactant treatment of meconium-induced acute lung injury. Am J Respir Crit Care Med 2000, 162:623-628.
56. Ikegami M, Rebello CM, Jobe AH: Surfactant inhibition by plasma: gestational age and surfactant treatment effects in preterm lambs. J Appl Physiol 1996, 81:2517-2522.
57. Yukitake K, Brown CL, Schlueter MA, et al.: Surfactant apoprotein A modifies the inhibitory effect of plasma proteins on surfactant activity in vivo. Pediatr Res 1995, 37:21-25.
58. Seeger W, Grube C, Gunther A, et al.: Surfactant inhibition by plasma proteins: differential sensitivity of various surfactant preparations. Eur Respir J 1993, 6:971-977.
59. Herting E, Rauprich P, Stichtenoth G, et al.: Resistance of different surfactant preparations to inactivation by meconium. Pediatr Res 2001, 50:44-49. This report demonstrates the inferiority of current surfactant preparations for use with meconium aspiration syndrome.
60. Sood SL, Balaraman V, Finn KC, et al.: Exogenous surfactants in a piglet model of acute respiratory distress syndrome. Am J Respir Cell Mol Biol 1996, 153:820-828.
61. Wiswell TE, Smith RM, Katz LB, et al.: Bronchopulmonary segmental lavage with Surfaxin (KL(4)-surfactant) for acute respiratory distress syndrome. Am J Respir Crit Care Med 1999, 160:1188-1195.
62. Wiswell TE, Knight GR, Finer NN, et al.: A multicenter, randomized, controlled trial comparing Surfaxin (Lucinactant) lavage with standard care for treatment of meconium aspiration syndrome. Pediatrics 2002, 109:1081-1087. One of the first reports of Surfaxin® use in human infants. Although hampered by small numbers, the study does demonstrate a trend toward amelioration of the severity of respiratory failure after Surfaxin® therapy.